We're taking a closer look at CRISPR Therapeutics AG today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 6.0% compared to 1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
-
CRISPR Therapeutics AG has moved 30.0% over the last year compared to 16.0% for the S&P 500 -- a difference of 14.0%
-
CRSP has an average analyst rating of buy and is -18.06% away from its mean target price of $87.78 per share
-
Its trailing 12 month earnings per share (EPS) is $-4.47
-
CRISPR Therapeutics AG has a trailing 12 month Price to Earnings (P/E) ratio of -16.1 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $-5.75 and its forward P/E ratio is -12.5
-
CRSP has a Price to Earnings Growth (PEG) ratio of 0.1, which shows the company is very undervalued compared to its earnings growth estimates.
-
The company has a Price to Book (P/B) ratio of 3.31 in contrast to the S&P 500's average ratio of 2.95
-
CRISPR Therapeutics AG is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
CRISPR Therapeutics AG has on average reported free cash flows of $-123869833.3 over the last four years, during which time they have grown by an an average of -24.1%
